In 2023, Tawil et al. [96] revealed nonrandom expression of PDPN within GBM cells, with an association with specific cell subpopulations enriched for inflammation- and coagulation-related genes, as well as a mesenchymal differentiation signature. This evidence concerns the gene PDPN and glioblastoma.